
|Videos|January 16, 2014
The Immunogenic Potential of Biosimilars: Should Health Care Providers Be Concerned?
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
Advertisement
Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
New CKD Outcome Set Tells Pharmacists What to Measure
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5


































































































